Category Archives: Pharmaceutical/Drug Litigation

Invokana and similar SGLT2 Class drugs

Invokana and similar SGLT2 class drugs used to treat Type 2 diabetes are being investigated for causing serious side effects including:

  • Kidney Failure
  • Diabetic Ketoacidosis
  • Dehydration Requiring Hospitalization
  • Heart Attack
  • Stoke
  • Death

SGLT2 class drugs:

  • Invokana® (canaglifozin)
  • Invokamet® (canaglifozin and metformin)
  • Farxiga® (dapaglifozin)
  • Xigduo XR® (dapagliflozin and metformin extended-release)
  • Glyxambi® (empagliflozin and linagliptin)

To refer a case contact Shane or Rebecca Langston at Langston Lawyers, PLLC


Xarelto side effects

Have you or a loved suffered from taking Xarelto?

Patients were not properly warned of the side effects of Xarelto, i.e uncontrollable internal bleeding and that this bleeding could not be reversed as easily as with other anticoagulants.

Other serious and Life-threatening Side Effects:

  • Uncontrolled bleeding events
  • Gastrointestinal Hemorrhage
  • Hematoma
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Hemoglobin Decrease
  • Cerebrovascular Accidents
  • Peripheral Edema
  • Dyspnea

Symptoms of Xarelto bleeding side effects may include:

  • Lethargy
  • Unusual bruising or bleeding
  • Pink or brown urine
  • Red or black tarry stools
  • Coughing up blood
  • Vomiting that resembles blood or looks like coffee grounds
  • Headaches
  • Bleeding from the gums
  • Frequent nose bleeds
  • Weakness and swelling in the hands, arms, lower legs, ankles or feet
  • Joint pain or swelling
  • Dizziness
  • Death

Call Langston Lawyers PLLC at 877-LAW-0008 for more information.

Drug company funding drug study to obtain desired results

A recent survey of clinical trials revealed that when a drug company funds a study, there is a 90 percent chance that the drug will be perceived as effective whereas a non-drug company-funded study will show favorable results 50 percent of the time. Drug companies that basically “purchase” the scientific result they want often results in a defective and harmful pharmaceutical.

If this practice has brought harm to you or a loved one, call us, help stop this abuse.


Heart attack or stroke after Testosterone therapy

Testosterone Replacement Therapy products for men have been linked to an increased risk of death, heart attack and stroke. In one study, researchers found men who used testosterone therapy were 30 percent more likely to have a heart attack, stroke, or die after three years of use. A second study found that men had a significant increase in risk of heart attack and stroke in just the first 90 days of testosterone therapy use. Testosterone therapy, such as the prescription topical treatments Androgel, Testim and Axiron, are used to help boost testosterone levels in men who have “Low T,” a deficiency of the male hormone.

Call Langston and Langston 888-329-0827



By: Irvin Jackson | Published: May 1st, 2014 (

A new report warns that use of the atypical anti psychotic medication Risperdal to treat autism may help reduce tantrums and improve focus, but it carries potentially serious risks, including weight gain, sleepiness and other side effects.

Risperdal (risperidone) was originally introduced for adults with schizophrenia, but it has been widely used for children with bi-polar disorders, autism, irritability, aggression and behavior disorders. It was the first drug ever approved by the FDA for treatment of some autism symptoms, and is the most widely known. In addition, it has been widely used off-label to treat hyperactivity and to reduce repetitive behaviors.

A report by the Simons Foundation Autism Research Initiative released this week, highlights a number of concerns over the potential side effects of Risperdal for autism treatment.

While experts indicate that Risperdal definitely can reduce tantrums and help autistic children focus on other methods of treatment, they also warn that it carries a serious risk of weight gain and fatigue. In addition, not everyone who is given the drug experiences the benefits and the problems frequently return when its use is stopped, experts told the Initiative.

On average, children given Risperdal experience about six pounds of weight gain within eight weeks of beginning therapy. While that may not seem like much to a 140 pound adult, for a 60 pound boy that gain is significant.

Weight gain associated with Risperdal and other atypical anti psychotics has also been associated with an increased risk of childhood diabetes. An August 2013 study published in the medical journal JAMA Psychiatry found that side effects of Risperdal and other similar drugs may triple the risk of diabetes for children.

Use of Risperdal among young boys has also been linked to a rare disorder known as gynecomastia, which involves the abnormal growth of breasts among males. Due to the known weight gain associated with the drug, these Risperdal breast development problems are often not immediately diagnosed until the breast growth significantly outpaces the weight gain.

In recent years, Johnson & Johnson has been facing a growing number of Risperdal gynecomastia lawsuits brought on behalf of teens and young adults, which allege that the drug maker failed to adequately warn consumers or the medical community about the risks associated with the medication. In some cases, plaintiffs indicate that boys using Risperdal have developed breasts measuring as large as a 38D cup size, often resulting in the need for surgical removal of the breasts.

This latest report published by the Simons Foundation Autism Research Initiative concludes that Risperdal should be used with caution, and only for children with the most serious autism symptoms, and only after other treatment options have failed.



NaturaLyte and GranuFlo

FMC says U.S. wrongful death lawsuits to be consolidated

Reuters | Thu Dec 13, 2012 1:57am EST

Dec 13 (Reuters) – Fresenius Medical Care , the world’s largest dialysis group, said a group of plaintiffs in the United States had moved to consolidate wrongful death lawsuits against the company over its NaturaLyte and GranuFlo products.

The suits generally allege that the two products carried inadequate labeling and warnings, causing harm to patients, FMC said, adding that it considered the suits to be without merit and was vigorously defending against them.

The company’s chief executive Ben Lipps said in a statement that FMC’s actions related to the products were appropriate and responsible.

“Both products are safe and effective and were reviewed and cleared by the Food and Drug Administration several years ago,” he said.

“I am confident of our position on this medical issue,” he said.

FMC’s North American subsidiary received a subpoena from the Massachusetts district attorney on Dec. 7 requesting documents in the case and was cooperating fully, the company said.

GranuFlo and Naturalyte

GranuFlo and Naturalyte are dialysates, used to treat acute and chronic kidney failure during hemodialysis. On May 25, 2012, the FDA issued a safety communication, warning that there had been complaints about dosing errors during hemodialysis, which could cause increased bicarbonate levels. Increased bicarbonate levels can cause metabolic alkalosis, which is associated with cardiopulmonary arrest, low blood pressure and cardiac arrhythmia.

Both products have been recalled and it has been alleged that the risks involved with using these products were not adequately disclosed. If proper warnings had been issued, health care providers would not have used these products.

If you or someone you know has been harmed by these products, please contact us at 1-888-329-0827 or you can simply sill out our online contact form for a free assessment of your case.

Side effects and direct injuries that can be caused by Pradaxa

Side effects and direct injuries that can be caused by Pradaxa

Potential Injuries:
•Brain hemorrhage
•Joint pain
•Intestinal problems
•Joint Inflammation
•Kidney bleeding
•Internal bleeding

Symptoms of excessive internal bleeding:
•Bleeding that lasts a long time
•Coughing up blood
•Joint pain
•Red or black stools
•Uncontrollable, severe bleeding
•Urine that is pink or brown
•Vomit that looks like coffee grounds
•Vomiting blood

If you or a loved one has experienced one or more of the following after being treated with Pradaxa please contact us.

Pradaxa sales have exceeded $1 billion

Pradaxa has generated more than a billion dollars for Boehringer Ingelheim since first reaching the market in 2011. In 2013, projected sales are worth $603,000,000.

Pradaxa’s success has been largely attributed to an aggressive marketing campaign by Boehringer Ingelheim, conducted at a cost of $67,000,000 during the year leading up to its release. Pradaxa was promoted as a more effective alternative to the widely-used warfarin, which requires frequent blood monitoring and dosage adjustments.

According to the Pradaxa gastrointestinal bleed lawsuit filed in Texas, there were 272,119 prescriptions written between October 2012 and March 2011. During the same period, 932 “adverse event reports” were submitted to the FDA, including 120 Pradaxa related deaths and 500 cases of severe internal bleeding. A further 856 adverse event reports were filed in the subsequent three months, 117 of them pertaining to death.